Remedy Robotics Raises $62M in Series B Funding to Advance AI-Enabled Vascular Intervention System

AI Insider

Source published: Site published:

Original article · فارسی

Insider Brief

  • Remedy Robotics has raised $62 million in Series B funding to develop its AI-powered N1 robotic system. The company plans to move the system toward clinical trials and possible FDA approval for procedures involving blood vessels in the brain, including stroke treatment.
  • The funding round was led by DCVC and included UC Investments, Skip Capital, Hostplus and existing investors. The money will support a planned clinical trial with the University of California, the use of prototype systems and further development of the system's ability to work on its own.
  • The N1 System is being designed to carry out blood vessel procedures at a hospital, from a remote location or on its own. However, it is still being developed and is not approved for sale or clinical use anywhere.

Remedy Robotics has raised $62 million in Series B funding to develop an AI-powered robotic system for procedures involving blood vessels in the brain. The company hopes to move the system toward clinical trials and possible FDA approval. These procedures include treatments for stroke.

According to Remedy, the funding round was led by DCVC. New investors UC Investments, Skip Capital and Hostplus also took part. Existing investors Build Collective, Blackbird, Divergent Capital and KdT Ventures also invested.

Remedy is developing its N1 System to perform procedures involving blood vessels in the brain, heart and other parts of the body. However, the company's first efforts to get regulatory approval will focus on procedures involving blood vessels in the brain. Co-founder and CEO Dr. David Bell said the new funding would help the company develop and bring the N1 System into use more quickly. He said the goal is to make specialized medical care available to more people, no matter where they live.

“Endovascular intervention is the gold standard treatment for stroke and many cardiovascular emergencies, yet access remains limited to a small number of hospitals,” Bell pointed out. “For these time-critical conditions, that’s devastating. Even when specialist intervention is available, treatment is often delayed, and complications are frustratingly common.”

What's Next?

Remedy said it plans to run an important clinical trial with the University of California. It also plans to put prototype N1 Systems into use through its clinical partners and continue developing the system's ability to work on its own. The company noted that the N1 System is still being developed. It is not approved for sale or clinical use anywhere.

According to Remedy, the N1 System uses machine learning to study medical images before a procedure, test possible ways to carry it out and line up 3D and 2D images in real time. The system is designed to perform complete procedures inside blood vessels using robots. It can be operated at the hospital, from a remote location or, eventually, on its own. The company said that fully independent operation is still being developed.

Remedy said its technology could help more people get specialized treatment for strokes and other serious heart and blood vessel emergencies. The company pointed to research suggesting that only 2.8% of stroke patients worldwide who could benefit from treatment inside blood vessels can actually access it.

In October 2025, Remedy reported that it had completed what it called the world's first remote procedures involving blood vessels in the brain using the N1 System. The company now works with more than 100 hospitals around the world. It plans to grow its clinical work through partnerships with SVIN Mission Thrombectomy and the Australian Stroke Alliance.

“This funding will allow our world-leading hardware, software, and machine learning teams to progress the N1 system towards clinical trials and potential FDA approval, while also developing additional features including full autonomy,” said Jake Sganga, CTO and co-founder of Remedy Robotics. “We are particularly excited to deepen our partnership with the University of California, having worked closely with their clinical experts since 2021, and as we prepare for our planned pivotal clinical trials to be held across the UC network.”